Kennedy Lawrence T. Jr 4

Accession 0000905148-24-001610

CIK 0001439725other

View on SEC.gov Company Profile

Filed

May 22, 8:00 PM ET

Accepted

May 23, 7:14 PM ET

Size

17.6 KB

Accession

0000905148-24-001610

Insider Transaction Report

Form 4

Period: 2024-05-21

BIODESIX INCBDSX

Kennedy Lawrence T. Jr

Director10% Owner

Transactions

Exercise/Conversion
Common Stock
2024-05-23+1,739,120→ 12,267,873 total(indirect: By Trust)
Award
Restricted Stock Units
2024-05-21+46,686→ 46,686 total
→ Common Stock (46,686 underlying)
Exercise/Conversion
Series A Non-Voting Convertible Preferred Stock
2024-05-23−43,478→ 0 total(indirect: By Trust)
→ Common Stock (1,739,120 underlying)
Exercise/Conversion
Common Stock
2024-05-23+2,608,720→ 2,775,386 total(indirect: By LLC)
Award
Stock Options (Right to Buy)
2024-05-21+37,050→ 37,050 total
Exercise: $1.57Exp: 2034-05-20→ Common Stock (37,050 underlying)
Exercise/Conversion
Series A Non-Voting Convertible Preferred Stock
2024-05-23−65,218→ 0 total(indirect: By LLC)
→ Common Stock (2,608,720 underlying)

Holdings

Common Stock
(indirect: By Trust)
10,304,824

Footnotes (6)

[F1]The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.
[F2]Reported amount has been adjusted to reflect the September 18, 2023 transfer of 687,515 shares of Common Stock previously held by the Lair BDSX GRAT 2022-3.2 to the Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 and the March 11, 2024 transfer of 34,526 shares of Common Stock previously held by the Lair BDSX GRAT 2022-3.2 to the Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 (the "March 11, 2024 Transfer"), each of which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Exchange Act. The Lair BDSX GRAT 2022-3.2 ceased to beneficially own any shares of Common Stock following the March 11, 2024 Transfer.
[F3]Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock.
[F4]These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.
[F5]Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
[F6]This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.

Documents

1 file

4
form4.xmlPrimary

Issuer

BIODESIX INC

CIK 0001439725

→

Entity typeother

Related Parties

filerCIK 0001830773

Filing Metadata

Form type: 4
Filed: May 22, 8:00 PM ET
Accepted: May 23, 7:14 PM ET
Size: 17.6 KB

View on SEC.gov